The Latest Breaking News from Grail

GRAIL shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 83.

GRAIL sees its Relative Strength Rating reach the 80-plus level.

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

Canyon’s Grail is an optimized gravel racing machine, but is it the pinnacle of gravel tech or death by integration?

Illumina is expected to release its second-quarter earnings next month, analysts expect a double-digit earnings dip.

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

Are we entering a new worldwide era for cancer screening?

Illumina stock rose Monday after the company said it would divest its cancer detection outfit, Grail, following a lengthy court battle.